Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Opportunities for 2-[$^{18}F$] Fluoro-2-Deoxy-D-Glucose PET/CT in Cervical-Vaginal Neuroendocrine Carcinoma: Case Series and Literature Review

  • Lin, Yin (Department of Nuclear Medicine, Taichung Veterans General Hospital) ;
  • Lin, Wan Y. (Department of Nuclear Medicine, Taichung Veterans General Hospital) ;
  • Liang, Ji A. (Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University) ;
  • Lu, Yu Y. (Department of Nuclear Medicine, Taichung Veterans General Hospital) ;
  • Wang, Hsin Y. (Department of Nuclear Medicine, Taichung Veterans General Hospital) ;
  • Tsai, Shih C. (Department of Nuclear Medicine, Taichung Veterans General Hospital) ;
  • Kao, Chia H. (Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University)
  • Published : 2012.12.01
⟨ Previous Next ⟩

Abstract

Objective: Neuroendocrine cervical carcinoma is a rare subtype of cervical cancer. These tumors exhibit an aggressive behavior with early regional lymph node and distant metastases. The purpose of our study was to describe five cases of neuroendocrine cervical-vaginal carcinoma and to discuss the potential of the 2-[$^{18}F$] fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ($^{18}F$-FDG PET/CT) scan for the detection of this rare malignancy. Materials and Methods: Five cases of cervical-vaginal neuroendocrine tumor were retrospectively collected, during a two year (from September 2009 to August 2011) period in our hospital. The clinical staging distributions were International Federation of Gynecology and Obstetrics (FIGO) stage IB2 (1 of 5), stage IIA (3 of 5) and stage IVA (1 of 5). Results: Two cases (cases 1 and 4) were restaged after $^{18}F$-FDG PET/CT scan in the initial staging process. Post-treatment $^{18}F$-FDG PET/CT scans, in three patients, revealed positive findings for tumor recurrence or lymph node metastases. Two patients (cases 2 and 3) died of tumor within two years. Conclusion: $^{18}F$-FDG PET/CT scan is a useful tool in cervical-vaginal neuroendocrine tumor. In its initial staging, the $^{18}F$-FDG PET/CT scan may help assess the possible nodal involvement or early hematogeneous spreading. We can also use the $^{18}F$-FDG PET/CT to detect local recurrence and to evaluate the treatment response after clinical manipulation.

Keywords

References

  1. Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011;30 Suppl 1:3-7
  2. Albores-Saavedra J, Gersell D, Gilks CB, Henson DE, Lindberg G, Santiago H, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 1997;121:34-39
  3. Sato Y, Shimamoto T, Amada S, Asada Y, Hayashi T. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int J Gynecol Pathol 2003;22:226-230 https://doi.org/10.1097/01.PGP.0000071046.12278.D1
  4. Krivak TC, McBroom JW, Sundborg MJ, Crothers B, Parker MF. Large cell neuroendocrine cervical carcinoma: a report of two cases and review of the literature. Gynecol Oncol 2001;82:187-191 https://doi.org/10.1006/gyno.2001.6254
  5. Reig Castillejo A, Membrive Conejo I, Foro Arnalot P, Rodriguez de Dios N, Algara Lopez M. Neuroendocrine small cell carcinoma of the uterine cervix. Clin Transl Oncol 2010;12:512-513 https://doi.org/10.1007/s12094-010-0546-0
  6. McCusker ME, Cote TR, Clegg LX, Tavassoli FJ. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol 2003;88:333-339 https://doi.org/10.1016/S0090-8258(02)00150-6
  7. Wang KL, Yang YC, Wang TY, Chen JR, Chen TC, Chen HS, et al. Neuroendocrine carcinoma of the uterine cervix: a clinicopathologic retrospective study of 31 cases with prognostic implications. J Chemother 2006;18:209-216 https://doi.org/10.1179/joc.2006.18.2.209
  8. Chung HH, Nam BH, Kim JW, Kang KW, Park NH, Song YS, et al. Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging 2010;37:1467-1473 https://doi.org/10.1007/s00259-010-1413-5
  9. Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix. Gynecol Oncol 2010;119:81-86 https://doi.org/10.1016/j.ygyno.2010.04.020
  10. Yilmaz M, Adli M, Celen Z, Zincirkeser S, Dirier A. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential. Nucl Med Commun 2010;31:526-531
  11. Jhingran A, Levenback C. Malignagnt diseases of the cervix: microinvasive and invasive carcinoma: diagnosis and management. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM. Comprehensive Gynecology, 5th ed. Philadelpia, PA: Mosby Elsevier;2007
  12. Henriksen E. The lymphatic spread of carcinoma of the cervix and of the body of the uterus; a study of 420 necropsies. Am J Obstet Gynecol 1949;58:924-942 https://doi.org/10.1016/0002-9378(49)90200-8
  13. Yang DH, Kim JK, Kim KW, Bae SJ, Kim KH, Cho KS. MRI of small cell carcinoma of the uterine cervix with pathologic correlation. AJR Am J Roentgenol 2004;182:1255-1258 https://doi.org/10.2214/ajr.182.5.1821255
  14. Okamoto Y, Tanaka YO, Nishida M, Tsunoda H, Yoshikawa H, Itai Y. MR imaging of the uterine cervix: imaging-pathologic correlation. Radiographics 2003;23:425-445; quiz 534-535 https://doi.org/10.1148/rg.232025065
  15. Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003;21:3651-3658 https://doi.org/10.1200/JCO.2003.01.102
  16. Unger JB, Lilien DL, Caldito G, Ivy JJ, Charrier A, Bellaire B. The prognostic value of pretreatment 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography scan in women with cervical cancer. Int J Gynecol Cancer 2007;17:1062-1067 https://doi.org/10.1111/j.1525-1438.2007.00902.x
  17. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-2225 https://doi.org/10.1016/S0140-6736(03)13778-6
  18. Trinh XB, Bogers JJ, Van Marck EA, Tjalma WA. Treatment policy of neuroendocrine small cell cancer of the cervix. Eur J Gynaecol Oncol 2004;25:40-44
  19. Belhocine TZ. 18F-FDG PET imaging in posttherapy monitoring of cervical cancers: from diagnosis to prognosis. J Nucl Med 2004;45:1602-1604
  20. Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2010;37:1270-1278 https://doi.org/10.1007/s00259-010-1417-1

Cited by

  1. 18F-FDG PET in small-cell cervical cancer: a prospective study with long-term follow-up vol.43, pp.4, 2012, https://doi.org/10.1007/s00259-015-3229-9
  2. Imaging and staging of neuroendocrine cervical cancer vol.43, pp.12, 2012, https://doi.org/10.1007/s00261-018-1667-0
  3. Neuroendocrine carcinoma of the cervix: a systematic review of the literature vol.18, pp.None, 2012, https://doi.org/10.1186/s12885-018-4447-x
  4. Clinical and MRI Characteristics of Uterine Cervical Adenocarcinoma: Its Variants and Mimics vol.20, pp.3, 2012, https://doi.org/10.3348/kjr.2018.0458
  5. 18F-FDG PET/computed tomography scan in patients with suspicion of recurrent neuroendocrine carcinoma of the cervix vol.42, pp.10, 2012, https://doi.org/10.1097/mnm.0000000000001432